On May 21, 2026, Eli Lilly reported that its triple-agonist candidate retatrutide delivered up to 28% mean weight loss among treatment completers on the 12 mg dose in the pivotal TRIUMPH-1 Phase 3 trial, which randomized roughly 2,339 people with obesity and followed them over 80 weeks. The 'triple-G' molecule — targeting GLP-1, GIP, and glucagon receptors — is positioned as a potential best-in-class challenger to semaglutide and tirzepatide. Lower-dose arms achieved about 26% (9 mg) and 19% (4 mg) mean weight loss versus 2% for placebo, and the positive topline readout was flagged as a new high-water mark for the obesity pipeline.